W
WAVEMAN · COMPANY
COAG · Hemab Therapeutics Holdings, Inc.
> Ask across nine datasets ⌘K
LIVE
TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475
← ALL COMPANIES

COAG

Hemab Therapeutics Holdings, Inc.
PHARMA & BIOTECH · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · CIK 0002114044
CLUSTER · 4 INSIDERSACTIVIST 13D☆ WATCH
INSIDER NET · 180D
$55.5M
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
4
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
56
13F, latest reported quarter
REVENUE GROWTH
-
XBRL, annual
NET MARGIN
-
CONVERSIONS · 180D
5
codes C/M, not in net · no price filed
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
net +$55.5M over 180 days
+$1.7M over 90 days · +$55.5M of it by a 10%+ holder
more than 98% of Pharma & Biotech
CONGRESS
no member of Congress has reported trading it
FUNDS
56 funds added or opened last quarter
below 53% of Pharma & Biotech
REVENUE
no revenue reported in any filing
MARGIN
no margin: this company reports no revenue to divide by
BUYBACKS
no share repurchases reported
SHORT
4.4% of shares outstanding short · 4.2 days to cover · settled 2026-07-31
more than 50% of Pharma & Biotech
THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET
4 insiders independently bought a net $55.5M — no planned sales are queued against it.
56 funds added or opened positions in the latest 13F quarter, of 56 holders.
AI DEN-MAB LLC disclosed a 5%+ stake (10.4%) in the last six months.
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN +30.6%
+30.6%12M
-27%+3%+32%+62%2026-052026-052026-062026-072026-072026-082026-09 2026-05-04 · Shah Rajeev M. bought $45.7M2026-05-04 · Shah Rajeev M. bought $2.4M2026-05-05 · Shah Rajeev M. bought $2.1M2026-06-16 · RA CAPITAL MANAGEMENT, L.P. bought $1.5M2026-05-06 · Shah Rajeev M. bought $1.3M2026-05-11 · RA Capital Healthcare Fund LP bought $643.0K2026-05-06 · Shah Rajeev M. bought $347.3K2026-05-11 · RA Capital Healthcare Fund LP bought $346.2K2026-05-05 · Shah Rajeev M. bought $256.7K2026-05-07 · RA Capital Healthcare Fund LP bought $192.8K2026-05-12 · Kolchinsky Peter bought $159.0K2026-06-15 · RA CAPITAL MANAGEMENT, L.P. bought $153.0K2026-05-19 · RA CAPITAL MANAGEMENT, L.P. bought $94.9K2026-05-07 · RA Capital Healthcare Fund LP bought $49.5K2026-05-08 · RA Capital Healthcare Fund LP bought $37.0K2026-05-20 · RA CAPITAL MANAGEMENT, L.P. bought $24.8K2026-05-11 · AI DEN-MAB LLC filed a 5%+ stake (10.4%)2026-05-11 · Access Industries Holdings LLC filed a 5%+ stake (10.4%)2026-05-11 · AI Biotechnology LLC filed a 5%+ stake (10.4%)2026-05-11 · Access Industries Management LLC filed a 5%+ stake (10.4%)2026-05-11 · Len Blavatnik filed a 5%+ stake (10.4%)
INSIDER BUY13D/G STAKE
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
4 insiders reported buying shares.
The record shows a net $55.5M bought by insiders over 180 days, 56 funds added last quarter. Every figure is a federal filing, dated the day it became public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
UTHRCPIXMRNAREGNLLYALNYELFCITRMDGLDNAVRTXNUVL
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, Hemab Therapeutics Holdings, Inc. insiders bought a net $55.5M of stock across 16 Form 4 purchases and sales, with 4 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-06.

INSIDER
FILED
SHARES
VALUE
RA CAPITAL MANAGEMENT, L.P.
—
BUY
2026-06-16
61,523.0
$1.5M
RA CAPITAL MANAGEMENT, L.P.
—
BUY
2026-06-15
6,146.0
$153.0K
RA CAPITAL MANAGEMENT, L.P.
—
BUY
2026-05-20
996.0
$24.8K
RA CAPITAL MANAGEMENT, L.P.
—
BUY
2026-05-19
3,802.0
$94.9K
Kolchinsky Peter
—
BUY
2026-05-12
6,387.0
$159.0K
16 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 11 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported
RA CAPITAL MANAGEMENT, L.P.
7,808,627.0 sh
$286.8M
NOVO HOLDINGS A/S
4,180,550.0 sh
$153.6M
FMR LLC
3,697,837.0 sh
$135.8M
Capital International Investors
3,603,876.0 sh
$132.4M
Deep Track Capital, LP
3,602,093.0 sh
$132.3M
5%+ owners
13D = intent to influence · 13G = passive
AI DEN-MAB LLC
ACTIVIST 13D · 2026-05-11
10.4%
Access Industries Holdings LLC
ACTIVIST 13D · 2026-05-11
10.4%
AI Biotechnology LLC
ACTIVIST 13D · 2026-05-11
10.4%
Access Industries Management LLC
ACTIVIST 13D · 2026-05-11
10.4%
Len Blavatnik
ACTIVIST 13D · 2026-05-11
10.4%
FORM 144
No planned-sale notices
No insider has notified an intent to sell. This is the panel to watch after a run-up.
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
PRODUCT
DeskBacktester CompaniesAccount
SUPPORT
FAQMethodology Contact
LEGAL
TermsPrivacy Accessibility
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-06 ALL SYSTEMS LIVE FOR MACHINES →